Drug intelligence / Profile preview

TOUCAN

Development stage: Preclinical
Lead developer: Linköping University
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

TOUCAN (Therapeutic-oligonucleotides activated by nucleases) is a nanocarrier system designed for the specific delivery of therapeutic nucleoside analogues to treat bacterial infections. This proof-of-concept system utilizes oligonucleotides as substrates that are activated by specific bacterial nucleases. Upon activation, it releases a therapeutic nucleoside, such as floxuridine, which then inhibits bacterial growth. The system has demonstrated efficacy in inhibiting *Staphylococcus aureus* growth in cultures and treating bacterial infections in a mouse model, with no observed toxicity in in vitro and in vivo studies. It aims to provide a safer delivery platform for nucleoside therapeutics by targeting specific nuclease activity associated with bacterial infections.

Other names: Therapeutic-oligonucleotides activated by nucleases

Targets

DNA polymerase III (DNA polymerase III (bacterial))TS (Thymidylate synthase)

Beyond the preview

Go deeper on TOUCAN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOUCAN.

Explore the full profile